Gemzar Gets Treatment IND for Advanced Pancreatic Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

INDIANAPOLIS--Eli Lilly and Company has received FDA approval to provide gemcitabine (Gemzar) to advanced pancreatic cancer patients through a Treatment Investigational New Drug program.

INDIANAPOLIS--Eli Lilly and Company has received FDA approvalto provide gemcitabine (Gemzar) to advanced pancreatic cancerpatients through a Treatment Investigational New Drug program.

The agent will be provided free of charge to patients who arenot candidates for surgery and who meet certain medical eligibilitycriteria. Patients may have been previously untreated or havehad one prior chemotherapy regimen. Physicians may call 1-800-621-7111for more information about the Treatment IND.

Articles in this issue
First Results of Avicidin Trials
Chemo Patients Often Develop Menstrual Irregularities
Growth Factor Receptor Blockade Moving From Laboratory to Clinic
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigation
Vinorelbine Plus Chemo Promising in Advanced Disease
Bone Substudy a Part of Tamoxifen Prevention Trial
Ultrasound Breast Screens Useful in Selected Women
New Roles Forecast for Endocrine Therapy
Antisense Drug Against BCL-2 Effective in Animal Cancer Models
Anticancer Drugs From Zeneca in Regulatory Phase of Development
Osteosarcoma Chemo Regimens Debated
Primary Chemotherapy Allows Breast-Conserving Surgery in French Study
Cancer Care, Inc. Sponsors Make-Up Clinics for Chemo Patients
$2 Billion Budget for NCI Proposed
Risk of Gyn Cancer Increases After Diagnosis of Breast Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Related Content
High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

Kyle Doherty
June 4th 2025
Article

Fruquintinib plus chemotherapy and a PD-1 inhibitor elicited an ORR of 80.0% with all partial responses in patients with treatment-naïve gastric/GEJ cancer.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer

Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer

Tony Berberabe, MPH
June 2nd 2025
Article

Disitamab vedotin, toripalimab, and trastuzumab demonstrated superior response rates and efficacy in HER2-overexpressing metastatic gastric cancers.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Elraglusib Plus Chemo Enhances Survival Vs Chemo Alone in Metastatic PDAC

Elraglusib Plus Chemo Enhances Survival Vs Chemo Alone in Metastatic PDAC

Jonah Feldman
June 1st 2025
Article

A survival benefit was noted when elraglusib was added to chemotherapy for patients with metastatic PDAC.

Neoadjuvant PAXG Significantly Improves EFS Over mFOLFIRINOX in Resectable PDAC

Neoadjuvant PAXG Significantly Improves EFS Over mFOLFIRINOX in Resectable PDAC

Jordyn Sava
June 1st 2025
Article

Cisplatin, nab-paclitaxel, gemcitabine, and capecitabine significantly improved EFS vs mFOLFIRINOX in resectable or borderline resectable pancreatic ductal adenocarcinoma.